Jaguar Health Files 8-K: Material Agreement & Financials
Ticker: JAGX · Form: 8-K · Filed: 2025-05-05T00:00:00.000Z
Sentiment: neutral
Topics: material-agreement, financials, corporate-action
TL;DR
Jaguar Health filed an 8-K on 5/5/25 for a material agreement and financials.
AI Summary
On May 5, 2025, Jaguar Health, Inc. filed an 8-K report detailing a material definitive agreement and financial statements. The company, formerly known as Jaguar Animal Health, Inc., is incorporated in Delaware and headquartered in San Francisco, California.
Why It Matters
This filing indicates significant corporate actions and financial reporting by Jaguar Health, Inc., which could impact investors and stakeholders.
Risk Assessment
Risk Level: low — This is a routine filing reporting a material agreement and financial statements, not indicating immediate operational or financial distress.
Key Numbers
- 001-36714 — SEC File Number (Identifies the company's filings with the SEC.)
- 46-2956775 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- Jaguar Health, Inc. (company) — Registrant
- May 5, 2025 (date) — Date of Report
- Jaguar Animal Health, Inc. (company) — Former Company Name
- Delaware (jurisdiction) — State of Incorporation
- San Francisco, California (location) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement filed by Jaguar Health, Inc. on May 5, 2025?
The filing indicates an 'Entry into a Material Definitive Agreement' as an item of disclosure, but the specific details of the agreement are not provided in this excerpt.
What financial statements are included in this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item of disclosure, but the specific financial statements are not detailed in this excerpt.
When was Jaguar Health, Inc. formerly known as Jaguar Animal Health, Inc.?
The company changed its name from Jaguar Animal Health, Inc. on August 30, 2013.
Where are Jaguar Health, Inc.'s principal executive offices located?
The principal executive offices are located at 200 Pine Street Suite 400, San Francisco, California, 94104.
What is the SIC code for Jaguar Health, Inc.?
The Standard Industrial Classification code for Jaguar Health, Inc. is 2834, Pharmaceutical Preparations.
From the Filing
0001193125-25-111996.txt : 20250505 0001193125-25-111996.hdr.sgml : 20250505 20250505060739 ACCESSION NUMBER: 0001193125-25-111996 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250505 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250505 DATE AS OF CHANGE: 20250505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 25910781 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 8-K 1 d935311d8k.htm 8-K 8-K false 0001585608 0001585608 2025-05-05 2025-05-05     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025     Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter)       Delaware   001-36714   46-2956775 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   200 Pine Street Suite 400     San Francisco , California     94104 (Address of Principal Executive Offices)     (Zip Code) Registrant’s Telephone Number, Including Area Code:  (415)   371-8300 (Former Name or Former Address, if Changed Since Last Report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, Par Value $0.0001 Per Share   JAGX   The Nasdaq Stock Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 1.01. Entry into a Material Definitive Agreement. As previously reported, on March 26, 2025, Jaguar Health, Inc. (the “Company”) entered into securities purchase agreements with certain accredited investors (collectively, the “Investors”), pursuant to which the Company agreed to sell to the Investors, and the Investors agreed to purchase from the Company, approximately $3.4 million aggregate principal amount of 6% convertible promissory notes and warrants to purchase shares of common stock of the Compa